NCT07107529
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07107529
Title Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Myeloma Network B.V.
Indications
Therapies
Age Groups: senior | adult
Covered Countries NOR | NLD | ITA | ESP


No variant requirements are available.